Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The aggressive low density lipoprotein lowering controversy.

J S Forrester1, C N Bairey-Merz, S Kaul

  • 1Department of Medicine, Cedars-Sinai Medical Center, and University of California at Los Angeles School of Medicine, USA.

Journal of the American College of Cardiology
|October 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Growth factors, cytokines, and vascular injury.

Trends in cardiovascular medicine·2011
Same author

The treatment of bacillary dysentery in Chinese soldiers with sulfaguanidine and sulfadiazine.

The American journal of the medical sciences·2010
Same author

Cutaneous diphtheria; a report of 140 cases.

The Journal of investigative dermatology·2010
Same author

Process of care is affected by the type of health insurance.

Evidence-based cardiovascular medicine·2005
Same author

Invasive treatment is not superior to conservative treatment in patients with non-Q-wave MI.

Evidence-based cardiovascular medicine·2005
Same author

Variation in use of invasive procedures in acute ischemic syndromes.

Evidence-based cardiovascular medicine·2005

Aggressively lowering low-density lipoprotein (LDL) with statins offers cardiovascular benefits, but optimal targets remain unclear. Further research is needed to balance benefits against potential adverse events.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Clinical trials confirm cardiovascular benefits of statin-induced low-density lipoprotein (LDL) lowering.
  • Unresolved questions persist regarding the relationship between LDL levels and cardiac events, optimal efficacy measures, and target LDL concentrations for therapy.

Purpose of the Study:

  • To review the current understanding of LDL lowering and cardiovascular events.
  • To discuss the complexities in determining the optimal LDL target for statin therapy.

Main Methods:

  • Review of recent clinical trials and epidemiological studies on LDL lowering and cardiovascular outcomes.
  • Analysis of conflicting data regarding the relationship between LDL levels and cardiac events.

Main Results:

Related Experiment Videos

  • The relationship between cardiac events and LDL levels is curvilinear, with diminishing benefits at lower LDL concentrations.
  • Conflicting results exist regarding the best LDL target, influenced by pretreatment levels and non-lipid-lowering effects of statins.

    • Conclusions:

    • Very aggressive LDL lowering (<80 mg/dL) may offer modest benefits beyond current guidelines but requires careful consideration of potential adverse events.
    • Ongoing trials are expected to clarify the optimal LDL targets and therapeutic strategies.